NEW YORK, NY. May 23, 2023 – The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics launched the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus. As the largest study of its kind in lupus, the Lupus Landmark Studywill follow 3,500 adults diagnosed with systemic lupus erythematosus (SLE). The Lupus Landmark Study is a key element of the Lupus Nexus, a state-of-the-art, patient-centric, collaborative research resource.

The  Lupus Nexus aims to transform lupus research and drug development through new information exchange capabilities. Thiscollaborative solution includes the diverse patient populations disproportionally affected by lupus and will be a resource for highly curated clinical data, patient-reported data, biological samples, and raw analyzed data to allow for global collaboration, innovation, and precision medicine approaches in lupus.

The full press release is available on the Lupus Therapeutics website.

Read full Press Release